AITRICS 'VitalCare', New Medical Technology Assessment Postponement Confirmed

AITRICS' emergency situation prediction solution 'AITRICS-VitalCare (AITRICS-VC)'
[Photo by AITRICS]

[Asia Economy Reporter Chunhee Lee] Medical artificial intelligence (AI) company AITRICS announced on the 16th that its emergency situation prediction solution, 'AITRICS VitalCare (AITRICS-VC),' has been confirmed as a subject for exemption from new medical technology evaluation by the National Evidence-based Healthcare Collaborating Agency (NECA).

The new medical technology evaluation exemption system is a system that exempts new medical technology evaluations only for medical devices approved by the Ministry of Food and Drug Safety that are judged to have no safety concerns. Through this, it becomes possible to use the technology as a non-reimbursed service in clinical settings, allowing clinical evidence to be established during the exemption period. Accordingly, VitalCare can now be used as a non-reimbursed service in medical clinical settings for about three years, including a two-year exemption period and up to 250 days for new medical technology evaluation.

The selected technologies include ▲ prediction of acute severe events (death, transfer to intensive care unit, cardiac arrest) that may occur within 6 hours in general wards ▲ prediction of sepsis that may occur within 4 hours in general wards ▲ prediction of mortality probability within 6 hours in intensive care units.

VitalCare is a medical AI software that monitors patient conditions in real time within hospitals to predict the risk of emergency situations early. It was developed based on the high unmet needs for monitoring technology that helps in-hospital medical staff predict specific emergency events and respond proactively. The company expects that the introduction of this solution will enable efficient work performance by medical staff in intensive care units and general wards, and increase the possibility of patient treatment.

VitalCare received approval from the Ministry of Food and Drug Safety in October last year based on the results of three confirmatory clinical trials conducted in July. In December of the same year, it was designated as the 27th innovative medical device in recognition of its innovativeness.

Kwangjun Kim, CEO of AITRICS, said, “We are pleased to achieve this success just over a month after being selected as an innovative medical device. The entry of VitalCare into the non-reimbursed market is expected to improve the efficiency of hospital resources by delivering accurate information in various in-hospital environments such as general wards and intensive care units.” He added, “Following this exemption decision, we will intensify sales and marketing efforts to expand VitalCare’s influence in the domestic market. We will also strive to accumulate clinical evidence for entry into the health insurance reimbursement system.”

This content was produced with the assistance of AI translation services.